NR Munjal

Vice Chairman & Managing Director, Ind-Swift Laboratories

The Indian Pharmaceutical Industry is evolving at an unprecedented pace wherein it caters to 40 percent of the generic demand in the US and 25 percent of all medicine in the UK. Globally, India ranks 3rd in terms of pharmaceutical production by volume and 14th by value. As formulators and drug marketers throughout the world face increasing pressure from unforeseeable circumstances such as the rapidly evolving CoronaVirus surge and the struggling economies of many nations mounts, a consistent supply of generic API has become the major requirement of formulators and drug marketers across the globe. In many emerging markets, where more drug products are consumed, reliable supplies are required.

Perfectly understanding the requirements, IndSwift Laboratories Limited has established itself as a reliable supplier of high-quality pharmaceutical products, with a strong emphasis on market driven regulatory approvals from all major health authorities, including the USFDA, ANVISA Brazil, Cofepris, KFDA, PMDA, and TGA. The company positions itself as a complete commercial supply package with over a dozen blockbusters selling drug products. The firm’s key strategy has been in maintaining a strong supply chain that not only meets current market demand but also assures customers of future prompt deliveries.

Ind-Swift Laboratories Limited, established in 1995, has been a long-committed player in providing high-quality Active Pharmaceutical Ingredients (APIs) to its consumers with the objective of bringing good health to everyone. With an established international footprint through official marketing channels set up in North America, China, and the UK, ISLLs presence has gained much attention as a player in the pharmaceutical space.

In an exclusive interview with Industry Outlook Magazine, NR Munjal, Vice Chairman & Managing Director at Ind-Swift Laboratories, elucidates us about the company’s unique proposition in the industry.
What Are The Key Strengths Of Your Company And The Major Facets That Set You Apart From Competitors Offering Similar Solutions?

We believe that an active sales and marketing team along with insights and coverage of global markets is a critical strength that ISLL holds. By covering nearly 50 percent of the existing market share across the globe for the supply of products such as Atorvastatin Calcium, Clarithromycin, Ezetimibe, Nitazoxanide, and Fexofenadine, ISLLs key strength lies in its product positioning, supply chain process, effective time management, and world-class quality control and assurance systems to bring products to the market.

ISLLs key differentiators include product manufacturing capacities ensuring the availability of metric ton quantities of product in accordance with customer requirements, regulatory support for both regulated and semi-regulated markets, an established distribution platform increasing customer reach, and a market-oriented pricing strategy.

Tell Us About Ind Swift’s Atorvastatin Calcium Crystalline/ Amorphous And How It Is Useful For Patients?
Atorvastatin Calcium, a member of the statin class of medications and a major revenue driver for Ind-Swift laboratories, has gained worldwide coverage in the medical fraternity to treat patients who are exposed to the risk of cardiac arrest due to increased cholesterol levels.

 Since the beginning of the FY2021, this product has had double-digit growth in terms of the percentage rise in consumption (in Kg) of 12.6 percent in the Latin America region, eight percent in the ROW markets, and over 8.4 percent change growth globally.

Additionally, the rising usage of combination therapies in tandem with Atorvastatin has helped drive up sales numbers, with Ind-Swift holding approximately 75 percent of the market share in the Latin America region, thereby making us one of the top/preferred suppliers of Atorvastatin Calcium.

Please Elaborate On Ind Swift’s Nitazoxanide And How It Is Useful For Patients?
 
Nitazoxanide is a broad-spectrum antiparasitic and antiviral drug used in the treatment of various helminthic, protozoal, and viral infections. It is indicated for the treatment of Cryptosporidium parvum and Giardia lamblia infections in immunocompetent individuals and has been repurposed for the treatment of influenza.

In clinical trials for chronic hepatitis C, an extended-release tablet (675 mg) was employed; however, this form is not currently commercialized or accessible for prescription. Nitazoxanide comes in two oral dosage forms: a 500 mg tablet and an oral suspension (100 mg per 5 ml when reconstituted).

Following the unprecedented demand for Nitazoxanide in many emerging markets and countries prone to digestive tract medical issues, Ind-Swift’s supply of this product nearly accounts for a market share of up to 75 percent of the exports in the regions of Brazil, Mexico, Egypt, SAARC and India.

Tell Us About The Ind Swift Laboratories Team. How Is Your Combined Experience Helping Your Company To Grow?
From a marketing/business development perspective, IndSwift Laboratories is one of the few companies which has had a consistent team over the years of its existence encouraging growth. From both technical and commercial backgrounds, our team is able to cater to regulated and semi-regulated markets with product-based (following country-wise registration requirements).
Starting from product development through our dedicated R&D center to commercialization, our combined experience allows us to promptly identify and negotiate pricing and supply terms, resulting in a smooth business experience for both the customer and ISLL as a supplier. This has indeed enabled Ind-Swift Laboratories to grow and proactively position itself as one of India's leading API suppliers.

What Are The Projects That Ind-Swift Laboratories Is Currently Engaged In? What Are Your Company’s Vision And Mission In The Coming Future?

Currently, we are working on CRAMS with a world-leading player who supplies OLED chemicals to Apple, Sony, and Samsung. Besides, we are also working with the Originator Company for the products going off patent for commercial supplies, as well as CRAMS for their requirements in New Drug Delivery System or Key Starting Material (KSM) for their new launches.

In addition, we are developing continuous flow chemistry for the hazardous process in the existing product lines. And as we proceed ahead, we envision significantly contributing to building a healthy world as one of the most preferred suppliers of drug products across the globe.

Our mission is in winning global customers through innovative quality pharmaceutical products. Encouraging a profitable, sustainable, and system-driven world-class pharmaceutical space by utilizing and effectively integrating the RIPCO value system as part of our core competencies wherein R stands for Respect, I-Integrity, P-Proactiveness, C-collaboration, and Openness.